Freenome, a pioneering biotech company, is thrilled to announce that Renown Health has joined forces as a partner for the Sanderson Study. This highly anticipated study will use Freenome’s groundbreaking multiomics platform, in combination with real-world data, to detect multiple cancers. This marks a major step forward in Freenome’s mission to revolutionize early cancer detection.
The Sanderson Study seeks to revolutionize the way we understand and predict cancer risk by combining traditional and real-world data to generate evidence of clinical validation for high- and elevated-risk populations.
By refining cancer classification and risk prediction models, the study is paving the way to bridge the gap between clinical research and everyday clinical practice, ensuring more accurate and safe outcomes for patients.
Freenome is revolutionizing cancer detection by using a pioneering multiomics platform that combines tumor and non-tumor signals with machine learning, allowing for early detection of cancer with a simple blood draw. This groundbreaking technology is transforming the way we diagnose, treat, and ultimately prevent cancer.
We are thrilled to be partnering with Freenome to launch this ambitious trial with the potential to revolutionize cancer detection. Through this study, led by Lee Schwartzberg, M.D., medical oncology section chief, at Renown, we are merging real-world patient data with multiomics technology to explore the possibilities of a personalized approach to early cancer detection.
Renown Health is proud to offer a diverse range of clinical trials to northern Nevada patients in need of specialized care. From oncology to cardiology, neurology to pediatrics, and pulmonology to name a few, there are numerous opportunities to gain access to cutting-edge treatments and therapies. Don’t miss out on the chance to have a positive impact on your health and wellbeing.
Cancer is a tragic reality in Nevada, claiming the lives of more than 5,400 Nevadans annually. This is a stark increase from the previous five-year plan estimate of 4,400 deaths per year, making it the second-leading cause of death in the Silver State. Such a devastating trend is a dire reminder for us to prioritize our health and wellbeing.
The Nevada Cancer Coalition and the Nevada Department of Health and Human Services have joined forces to develop the Nevada Cancer Plan 2021-2025 – a strategic framework that seeks to revolutionize cancer prevention, detection, diagnosis, and treatment through research and innovation. By working together, we can create a brighter future for all those affected by cancer.
Accessing and taking part in clinical trials is an essential part of the plan, and Renown views the Sanderson Study as an especially meaningful opportunity for its participants.
At the William N. Pennington Cancer Institute, we are dedicated to providing the highest quality of care for our community and to improving cancer outcomes through research. That is why we are thrilled to announce our partnership with Freenome, which has the potential to make a long-held dream come true: discovering cancer early when treatment is most effective. Through this collaboration, we will strive to make a positive impact in our fight against this disease.
The Sanderson Study is an ambitious endeavor that seeks to enroll 8,000 patients from across the United States through Freenome’s clinical study partner network and numerous regional health systems. This groundbreaking research promises to revolutionize the way we understand and treat disease.
Renown is dedicated to improving the health and well-being of Nevada’s communities through innovative research. By combining real-world data with multiomics, we are on the brink of revolutionizing the diagnosis of cancer in its earliest stages. According to Lance Baldo, M.D., Chief Medical Officer at Freenome, this breakthrough could be life-changing for patients and their families.
Freenome has dedicated its clinical studies to honor the memory of those who have fought cancer, including the beloved father of one of its engineers, Tim Sanderson. In his honor, Freenome proudly carries on its mission to provide early detection and prevention of cancer.
Freenome, a biotechnology company in South San Francisco, California, has developed a revolutionary multiomics platform to detect cancer using a simple blood test. By combining its deep knowledge of molecular biology with advanced computational biology and machine learning, Freenome is able to identify disease-associated patterns among billions of circulating cell-free biomarkers, providing a powerful tool for early detection of cancer.
About Renown Health’s William N. Pennington Cancer Institute
The William N. Pennington Cancer Research Institute is at the forefront of cancer care in northern Nevada, providing comprehensive, multidisciplinary care and educating the next generation of healthcare providers. We strive to improve treatments and outcomes through active participation in research, making a real difference in the lives of the community we serve.
About Renown Health
Renown Health is a remarkable, not-for-profit, integrated healthcare network that brings together an impressive workforce of 7,000 professionals in Nevada, Lake Tahoe and northeast California.
With a culture of excellence, determination and innovation, Renown offers a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group, an urgent care network and the largest, locally owned not-for-profit insurance company, Hometown Health. Come experience the best of healthcare with Renown Health.